Skip to main content
Top
Published in: Journal of Gastroenterology 1/2011

01-01-2011 | Review

Natural history of hepatitis B virus infection: pediatric perspective

Author: Yen-Hsuan Ni

Published in: Journal of Gastroenterology | Issue 1/2011

Login to get access

Abstract

Hepatitis B virus (HBV) infection is an important disease globally. Chronic HBV infection may result in serious complications. Its transmission may be either perinatal or horizontal. Perinatal transmission is particularly important after the implementation of a universal vaccination program. Through either route, chronic carrier status is usually established in early childhood. The course of the disease course is determined by the host–virus interaction. The host’s immune system initially tolerates the virus, and then gradually attempts to clear it. The virus, on the other hand, tries to avoid host immune system attack by a strategy involving targeted epitope mutations. By generating mutants, the virus can survive attacks from the host’s immune system, enabling the infection to persist. Different individuals have different responses to HBV infection; genetic polymorphisms in cytokines, hormones, and other immune modulators may affect the final outcome of chronic HBV infection. Due to the implementation of a universal infant HBV vaccination program, HBV infection is now under control. Unfortunately, there still are some cases of vaccination failure. Very high maternal viremia, in utero infection, or escape mutants are possible reasons for vaccination failure. Immunocompromised hosts also risk vaccination failure. Blood or organ donors with occult HBV infection are possible sources for immunocompromised hosts. These victims of vaccination failure may exhibit a different disease course due to chronic HBV infection from those who acquired the infection before the universal vaccination era. The achievement of our ultimate goal of HBV elimination depends on a globally effective universal vaccination program, as well as the application of some novel successful medications to control those who are already infected.
Literature
1.
go back to reference Beasley RP, Stevens CE. Epidemiology of hepatitis B virus infection in Taiwan. In: Sung JL, Yu JY, Wang TH, editors. Proceedings of the International Symposium on Hepatitis in Taipei. Taipei: Gastroenterologic Society of the Republic of China, pp. 1–10. Beasley RP, Stevens CE. Epidemiology of hepatitis B virus infection in Taiwan. In: Sung JL, Yu JY, Wang TH, editors. Proceedings of the International Symposium on Hepatitis in Taipei. Taipei: Gastroenterologic Society of the Republic of China, pp. 1–10.
2.
go back to reference Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. Baseline seroepidemiology of hepatitis B virus in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol. 1986;18:301–7.CrossRefPubMed Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. Baseline seroepidemiology of hepatitis B virus in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol. 1986;18:301–7.CrossRefPubMed
3.
go back to reference Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292:771–4.CrossRefPubMed Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292:771–4.CrossRefPubMed
4.
5.
go back to reference Chu CM. Toward control of hepatitis B in the Asia-Pacific Region—natural history of chronic hepatitis B virus infection adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2000;15:E25–30.CrossRefPubMed Chu CM. Toward control of hepatitis B in the Asia-Pacific Region—natural history of chronic hepatitis B virus infection adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2000;15:E25–30.CrossRefPubMed
6.
go back to reference Yuen MF, Lai CL. Toward control of hepatitis B in the Asia–Pacific region—natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2000;15:E20–4. Yuen MF, Lai CL. Toward control of hepatitis B in the Asia–Pacific region—natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2000;15:E20–4.
7.
go back to reference Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis. 2006;26:130–41.CrossRefPubMed Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis. 2006;26:130–41.CrossRefPubMed
8.
go back to reference Ni YH, Chang MH, Chen PJ, Tsai KS, Hsu HY, Chen HL, et al. Viremia profiles in children with chronic hepatitis B infection and spontaneous e antigen seroconversion. Gastroenterology. 2007;132:2340–5.CrossRefPubMed Ni YH, Chang MH, Chen PJ, Tsai KS, Hsu HY, Chen HL, et al. Viremia profiles in children with chronic hepatitis B infection and spontaneous e antigen seroconversion. Gastroenterology. 2007;132:2340–5.CrossRefPubMed
9.
go back to reference Chang MH, Hsu HY, Ni YH, Tsai KS, Lee PI, Chen PJ, et al. Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B seroconversion and maternal hepatitis B surface antigen. J Hepatol. 1998;28:915–22. Chang MH, Hsu HY, Ni YH, Tsai KS, Lee PI, Chen PJ, et al. Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B seroconversion and maternal hepatitis B surface antigen. J Hepatol. 1998;28:915–22.
10.
go back to reference Ni YH, Chang MH, Hsu HY, Tsuei DJ. Longitudinal study on mutation profiles of core promoter and precore regions of hepatitis B virus genome in children. Pediatr Res. 2004;56:396–9.CrossRefPubMed Ni YH, Chang MH, Hsu HY, Tsuei DJ. Longitudinal study on mutation profiles of core promoter and precore regions of hepatitis B virus genome in children. Pediatr Res. 2004;56:396–9.CrossRefPubMed
11.
go back to reference Ni YH, Chang MH, Hsu HY, Chen HL. Long-term follow-up study of core gene deletion mutants in children with chronic hepatitis B virus infection. Hepatology. 2000;32:124–8.CrossRefPubMed Ni YH, Chang MH, Hsu HY, Chen HL. Long-term follow-up study of core gene deletion mutants in children with chronic hepatitis B virus infection. Hepatology. 2000;32:124–8.CrossRefPubMed
12.
go back to reference Ni YH, Chang MH, Hsu HY, Tung YC, Chen HL, Wang KJ, et al. Mutations of T cell epitopes on the hepatitis B virus surface gene in children with chronic infection and hepatocellular carcinoma. Am J Gastroenterol. 2008;103:1004–9.CrossRefPubMed Ni YH, Chang MH, Hsu HY, Tung YC, Chen HL, Wang KJ, et al. Mutations of T cell epitopes on the hepatitis B virus surface gene in children with chronic infection and hepatocellular carcinoma. Am J Gastroenterol. 2008;103:1004–9.CrossRefPubMed
13.
go back to reference Wu JF, Wu TC, Chen CH, Ni YH, Chen HL, Hsu HY, et al. Serum levels of interleukin 10 and 12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology. 2010;138:165–72.CrossRefPubMed Wu JF, Wu TC, Chen CH, Ni YH, Chen HL, Hsu HY, et al. Serum levels of interleukin 10 and 12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology. 2010;138:165–72.CrossRefPubMed
14.
go back to reference Wu JF, Tsai WY, Hsu HY, Ni YH, Chen HL, Tsuei DJ, et al. The effect of puberty onset on spontaneous hepatitis B virus e antigen seroconversion in men. Gastroenterology. 2010;138:942–8.CrossRefPubMed Wu JF, Tsai WY, Hsu HY, Ni YH, Chen HL, Tsuei DJ, et al. The effect of puberty onset on spontaneous hepatitis B virus e antigen seroconversion in men. Gastroenterology. 2010;138:942–8.CrossRefPubMed
15.
go back to reference Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, et al. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol. 2006;44:39–46.CrossRefPubMed Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, et al. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol. 2006;44:39–46.CrossRefPubMed
16.
go back to reference Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr. 2009;48:203–8.CrossRefPubMed Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr. 2009;48:203–8.CrossRefPubMed
17.
go back to reference Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47:844–53. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47:844–53.
18.
go back to reference Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–28.PubMed Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–28.PubMed
19.
go back to reference Chang MH, Chen THH, Hsu HM, Wu TC, Kong MS, Liang DC, et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res. 2005;11:7953–7.CrossRefPubMed Chang MH, Chen THH, Hsu HM, Wu TC, Kong MS, Liang DC, et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res. 2005;11:7953–7.CrossRefPubMed
20.
22.
go back to reference Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow up study. J Pediatr. 1998;133:374–7.CrossRefPubMed Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow up study. J Pediatr. 1998;133:374–7.CrossRefPubMed
23.
go back to reference Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology. 2003;38:1075–86.CrossRefPubMed Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology. 2003;38:1075–86.CrossRefPubMed
24.
go back to reference Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA. 1990;87:6599–603.CrossRefPubMed Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA. 1990;87:6599–603.CrossRefPubMed
25.
go back to reference Hsu SC, Chang MH, Ni YH, Hsu HY, Lee CY. Horizontal transmission of hepatitis B virus in children. J Pediatr Gastroenterol Nutr. 1993;16:66–9.CrossRefPubMed Hsu SC, Chang MH, Ni YH, Hsu HY, Lee CY. Horizontal transmission of hepatitis B virus in children. J Pediatr Gastroenterol Nutr. 1993;16:66–9.CrossRefPubMed
26.
go back to reference Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR. 2008;57(RR08):1–20.PubMed Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR. 2008;57(RR08):1–20.PubMed
27.
go back to reference Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR. 2006;55(RR16):1–25.PubMed Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR. 2006;55(RR16):1–25.PubMed
28.
go back to reference Chang MH, Lee CY, Chen DS, Hsu HC, Lai MY. Fulminant hepatitis in children in Taiwan: the important role of hepatitis B virus. J Pediatr. 1987;111:34–9.CrossRefPubMed Chang MH, Lee CY, Chen DS, Hsu HC, Lai MY. Fulminant hepatitis in children in Taiwan: the important role of hepatitis B virus. J Pediatr. 1987;111:34–9.CrossRefPubMed
29.
go back to reference Hsu HY, Chang MH, Lee CY, Hsieh KH, Ni YH, Chen PJ, et al. Precore mutant of hepatitis B virus in childhood fulminant hepatitis B: an infrequent association. J Infect Dis. 1995;171:776–81.PubMed Hsu HY, Chang MH, Lee CY, Hsieh KH, Ni YH, Chen PJ, et al. Precore mutant of hepatitis B virus in childhood fulminant hepatitis B: an infrequent association. J Infect Dis. 1995;171:776–81.PubMed
30.
go back to reference Chang MH, Hwang LY, Hsu HC, Lee CY, Beasley RP. Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period: clinical and liver histologic studies. Hepatology. 1988;8:374–7.CrossRefPubMed Chang MH, Hwang LY, Hsu HC, Lee CY, Beasley RP. Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period: clinical and liver histologic studies. Hepatology. 1988;8:374–7.CrossRefPubMed
32.
go back to reference Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology. 2007;132:1287–93.CrossRefPubMed Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology. 2007;132:1287–93.CrossRefPubMed
33.
go back to reference Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis B e antigen sero-conversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology. 1995;22:1387–92.PubMed Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis B e antigen sero-conversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology. 1995;22:1387–92.PubMed
34.
go back to reference Chang MH, Sung JL, Lee CY, Chen CJ, Chen JS, Hsu HY, et al. Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children. J Pediatr. 1989;115:385–90.CrossRefPubMed Chang MH, Sung JL, Lee CY, Chen CJ, Chen JS, Hsu HY, et al. Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children. J Pediatr. 1989;115:385–90.CrossRefPubMed
35.
go back to reference Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology. 2010;51:435–44.PubMed Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology. 2010;51:435–44.PubMed
36.
go back to reference Bortolotti F, Guido M, Bartolacci S, Cadrobbi P, Crivellaro C, Noventa F, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology. 2006;43:556–62.CrossRefPubMed Bortolotti F, Guido M, Bartolacci S, Cadrobbi P, Crivellaro C, Noventa F, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology. 2006;43:556–62.CrossRefPubMed
37.
go back to reference Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139:474–82.CrossRefPubMed Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139:474–82.CrossRefPubMed
38.
go back to reference Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.CrossRefPubMed Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.CrossRefPubMed
39.
go back to reference Wen WH, Chang MH, Hsu HY, Ni YH, Chen HL. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr. 2004;144:397–9.CrossRefPubMed Wen WH, Chang MH, Hsu HY, Ni YH, Chen HL. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr. 2004;144:397–9.CrossRefPubMed
40.
go back to reference Chang MH, Chen PJ, Chen JY, Lai MY, Hsu HC, Lian DC, et al. Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. Hepatology. 1991;13:316–20.CrossRefPubMed Chang MH, Chen PJ, Chen JY, Lai MY, Hsu HC, Lian DC, et al. Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. Hepatology. 1991;13:316–20.CrossRefPubMed
41.
go back to reference Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–83.CrossRefPubMed Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–83.CrossRefPubMed
42.
go back to reference Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol. 2002;17:643–50.CrossRefPubMed Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol. 2002;17:643–50.CrossRefPubMed
43.
go back to reference Ni YH, Chang MH, Wang KJ, Hsu HY, Chen HL, Kao JH, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology. 2004;127:1733–8.CrossRefPubMed Ni YH, Chang MH, Wang KJ, Hsu HY, Chen HL, Kao JH, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology. 2004;127:1733–8.CrossRefPubMed
44.
go back to reference Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol. 2004;72:363–9.CrossRefPubMed Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol. 2004;72:363–9.CrossRefPubMed
45.
go back to reference Hsu HY, Chang MH, Hsieh KH, Lee CY, Lin HH, Hwang LH, et al. Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology. 1992;15:770–6.CrossRefPubMed Hsu HY, Chang MH, Hsieh KH, Lee CY, Lin HH, Hwang LH, et al. Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology. 1992;15:770–6.CrossRefPubMed
46.
go back to reference Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis. 2007;27:152–60.CrossRefPubMed Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis. 2007;27:152–60.CrossRefPubMed
47.
go back to reference Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118–29.CrossRefPubMed Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118–29.CrossRefPubMed
49.
go back to reference Carman WF, Fagan EA, Hadziyannis S, Karayiannis P, Tassopoulos NC, Williams R, et al. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology. 1991;14:219–22.CrossRefPubMed Carman WF, Fagan EA, Hadziyannis S, Karayiannis P, Tassopoulos NC, Williams R, et al. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology. 1991;14:219–22.CrossRefPubMed
50.
go back to reference Nakahori S, Yokosuka O, Ehata T, Chuang WL, Imazeki F, Ito Y, et al. Detection of hepatitis B virus precore stop codon mutants by selective amplification method: frequent detection of precore mutants in hepatitis B e antigen positive healthy carriers. J Gastroenterol Hepatol. 1995;10:419–25.CrossRefPubMed Nakahori S, Yokosuka O, Ehata T, Chuang WL, Imazeki F, Ito Y, et al. Detection of hepatitis B virus precore stop codon mutants by selective amplification method: frequent detection of precore mutants in hepatitis B e antigen positive healthy carriers. J Gastroenterol Hepatol. 1995;10:419–25.CrossRefPubMed
51.
go back to reference Ni YH, Chang MH, Hsu HY, Tsuei DJ. Different hepatitis B virus core gene mutations in children with chronic infection and hepatocellular carcinoma. Gut. 2003;52:122–5.CrossRefPubMed Ni YH, Chang MH, Hsu HY, Tsuei DJ. Different hepatitis B virus core gene mutations in children with chronic infection and hepatocellular carcinoma. Gut. 2003;52:122–5.CrossRefPubMed
52.
go back to reference Tordjeman M, Fontan G, Rabillon V, Martin J, Trepo C, Hoffenbach A, et al. Characterization of minor and major antigenic regions within the hepatitis B virus nucleocapsids. J Med Virol. 1993;41:221–9.CrossRefPubMed Tordjeman M, Fontan G, Rabillon V, Martin J, Trepo C, Hoffenbach A, et al. Characterization of minor and major antigenic regions within the hepatitis B virus nucleocapsids. J Med Virol. 1993;41:221–9.CrossRefPubMed
53.
go back to reference Raimondo G, Burk RD, Lieberman HM, Muschel J, Hadziyannis SJ, Will H, et al. Interrupted replication of hepatitis B virus in liver tissue of HBsAg carriers with hepatocellular carcinoma. Virology. 1988;166:103–12.CrossRefPubMed Raimondo G, Burk RD, Lieberman HM, Muschel J, Hadziyannis SJ, Will H, et al. Interrupted replication of hepatitis B virus in liver tissue of HBsAg carriers with hepatocellular carcinoma. Virology. 1988;166:103–12.CrossRefPubMed
54.
go back to reference Liu CJ, Jeng YM, Chen CL, Cheng HR, Chen PJ, Chen TC, et al. Hepatitis B virus basal core promoter mutation and DNA load correlate with expression of hepatitis B core antigen in patients with chronic hepatitis B. J Infect Dis. 2009;199:742–9.CrossRefPubMed Liu CJ, Jeng YM, Chen CL, Cheng HR, Chen PJ, Chen TC, et al. Hepatitis B virus basal core promoter mutation and DNA load correlate with expression of hepatitis B core antigen in patients with chronic hepatitis B. J Infect Dis. 2009;199:742–9.CrossRefPubMed
55.
go back to reference Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology. 1999;29:976–84.CrossRefPubMed Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology. 1999;29:976–84.CrossRefPubMed
56.
go back to reference Tai PC, Banik D, Lin GI, Pai S, Pai K, Lin MH, et al. Novel and frequent mutation of HBV coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. J Virol. 1997;71:4852–6.PubMed Tai PC, Banik D, Lin GI, Pai S, Pai K, Lin MH, et al. Novel and frequent mutation of HBV coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. J Virol. 1997;71:4852–6.PubMed
57.
go back to reference Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet. 2009;41:591–5.CrossRefPubMed Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet. 2009;41:591–5.CrossRefPubMed
58.
go back to reference Yeh SH, Chiu CM, Chen CL, Lu SF, Hsu HC, Chen DS, et al. Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. Int J Cancer. 2007;120:1610–7.CrossRefPubMed Yeh SH, Chiu CM, Chen CL, Lu SF, Hsu HC, Chen DS, et al. Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. Int J Cancer. 2007;120:1610–7.CrossRefPubMed
59.
go back to reference Yu MW, Cheng SW, Lin MW, Yang SY, Liaw YF, Chang HC, et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst. 2000;92:2023–8. Yu MW, Cheng SW, Lin MW, Yang SY, Liaw YF, Chang HC, et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst. 2000;92:2023–8.
60.
go back to reference Paz-y-Miño C, Witte T, Robles P, Llumipanta W, Díaz M, Arévalo M. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population. Cancer Genet Cytogenet. 2009;189:71–6.CrossRefPubMed Paz-y-Miño C, Witte T, Robles P, Llumipanta W, Díaz M, Arévalo M. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population. Cancer Genet Cytogenet. 2009;189:71–6.CrossRefPubMed
61.
go back to reference Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst. 2001;93:1644–51.CrossRefPubMed Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst. 2001;93:1644–51.CrossRefPubMed
62.
go back to reference Yeh SH, Chen PJ. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology. 2010;78(Suppl 1):172–9.CrossRefPubMed Yeh SH, Chen PJ. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology. 2010;78(Suppl 1):172–9.CrossRefPubMed
63.
go back to reference Ni YH, Chang MH, Hsu HY, Hsu HC, Chen CC, Chen WJ, et al. Hepatocellular carcinoma in childhood. Cancer. 1991;68:1737–41.CrossRefPubMed Ni YH, Chang MH, Hsu HY, Hsu HC, Chen CC, Chen WJ, et al. Hepatocellular carcinoma in childhood. Cancer. 1991;68:1737–41.CrossRefPubMed
64.
go back to reference Tsuei DJ, Hsu HC, Lee PH, Jeng YM, Pu YS, Chen CN, et al. RBMY, a male germ cell-specific RNA-binding protein, activated in human liver cancers and transforms rodent fibroblasts. Oncogene. 2004;23:5815–22.CrossRefPubMed Tsuei DJ, Hsu HC, Lee PH, Jeng YM, Pu YS, Chen CN, et al. RBMY, a male germ cell-specific RNA-binding protein, activated in human liver cancers and transforms rodent fibroblasts. Oncogene. 2004;23:5815–22.CrossRefPubMed
65.
go back to reference Hsu HY, Chang MH, Ni YH, Lee PI. Cytokine release of peripheral blood mononuclear cells in children with chronic hepatitis B virus infection. J Pediatr Gastroenterol Nutr. 1999;29:540–5.CrossRefPubMed Hsu HY, Chang MH, Ni YH, Lee PI. Cytokine release of peripheral blood mononuclear cells in children with chronic hepatitis B virus infection. J Pediatr Gastroenterol Nutr. 1999;29:540–5.CrossRefPubMed
67.
go back to reference Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immuno- prophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transplant. 2010;16:300–7. Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immuno- prophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transplant. 2010;16:300–7.
68.
go back to reference Otte JB. History of pediatric liver transplantation. Where are we coming from? Where do we stand? Pediatr Transplant. 2002;6:378–87.CrossRefPubMed Otte JB. History of pediatric liver transplantation. Where are we coming from? Where do we stand? Pediatr Transplant. 2002;6:378–87.CrossRefPubMed
69.
go back to reference Su WJ, Ho MC, Ni YH, Wu JF, Jeng YM, Chen HL, et al. Clinical course of de novo hepatitis B infection after pediatric liver transplantation. Liver Transpl. 2010;16:215–21.CrossRefPubMed Su WJ, Ho MC, Ni YH, Wu JF, Jeng YM, Chen HL, et al. Clinical course of de novo hepatitis B infection after pediatric liver transplantation. Liver Transpl. 2010;16:215–21.CrossRefPubMed
70.
go back to reference Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang. 2004;86:28–40. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang. 2004;86:28–40.
71.
go back to reference Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after universal hepatitis B vaccination. Ann Intern Med. 2001;135:796–800.PubMed Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after universal hepatitis B vaccination. Ann Intern Med. 2001;135:796–800.PubMed
72.
go back to reference Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336:325–9.CrossRefPubMed Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336:325–9.CrossRefPubMed
73.
go back to reference Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after nationwide vaccination program in Taiwan. Gut. 2004;53:1499–503.CrossRefPubMed Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after nationwide vaccination program in Taiwan. Gut. 2004;53:1499–503.CrossRefPubMed
74.
go back to reference Hsu HY, Chang MH, Ni YH, Chiang CL, Chen HL, Wu JF, et al. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis. 2010;201:1192–200.CrossRefPubMed Hsu HY, Chang MH, Ni YH, Chiang CL, Chen HL, Wu JF, et al. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis. 2010;201:1192–200.CrossRefPubMed
75.
go back to reference Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010;362:2271–81.CrossRefPubMed Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010;362:2271–81.CrossRefPubMed
76.
go back to reference van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003;10:294–7.CrossRefPubMed van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003;10:294–7.CrossRefPubMed
77.
go back to reference Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16:94–103.CrossRefPubMed Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16:94–103.CrossRefPubMed
78.
go back to reference Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA. 2000;284:3040–2.CrossRefPubMed Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA. 2000;284:3040–2.CrossRefPubMed
Metadata
Title
Natural history of hepatitis B virus infection: pediatric perspective
Author
Yen-Hsuan Ni
Publication date
01-01-2011
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 1/2011
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-010-0304-7

Other articles of this Issue 1/2011

Journal of Gastroenterology 1/2011 Go to the issue